Overcoming the accuracy-generalization tradeoff in docking and scoring for prospective virtual screening

Virtual screening promises access to tens of billions of synthetically accessible, diverse compounds, yet it is rarely used as a primary hit-discovery strategy in contemporary drug-discovery campaigns. We argue that this gap reflects the real-world underperformance of the underlying docking and scoring methods: classical docking is generalizable but limited in accuracy by simple functional forms and parsimonious parameterization, whereas recent machine-learning approaches are highly expressive but do not generalize well to novel molecules and pockets, their reported accuracy often inflated by train-test leakage. To address these challenges, we introduce DODock and DOScore, docking and scoring ML/physics hybrid frameworks that are also highly expressive, yet generalize much better out of distribution compared with the prior ML approaches.

This generalization has been prospectively tested in several ways. First, DODock’s blind prediction of a drug candidate binding to PCSK9 was compared to the crystal structure that was subsequently solved, recovering the binding pose to 1.2 Angstrom RMSD. We also used DODock and DOScore in prospective virtual screening campaigns against four therapeutic targets, spanning an ectoenzyme (CD73), a kinase (IRAK4), an extended-substrate protease (FXI), and an allosteric inhibition of protein-protein interface (IL17). These screens yielded many chemically novel, biochemically and cellularly active inhibitors. In the case of CD73, which is a historically challenging target for virtual screening, our screen resulted in a roughly hundredfold improvement in hit rate over a recent machine-learning screen. Our results indicate that the apparent ceiling in the accuracy of virtual screening that seemed to have somewhat plateaued in the last two decades is not fundamental, and that structure-based interrogation of ultralarge chemical space may eventually become a credible primary route to novel chemical matter.

Join the webinar

Deep Origin Chief Scientific Officer Garegin Papoian will present these results, with Chief Business Officer Natalie Ma on what they mean for teams evaluating virtual screening, followed by a live Q&A: Useful Generalization is the Benchmark That Matters — Wednesday, September 2, 2026 at 1:00 PM PT.